Product
Tolvaptan
6 clinical trials
8 indications
Indication
ARPKDIndication
SafetyIndication
VasopressinIndication
Inappropriate SecretionIndication
HyponatremiaIndication
SIADHClinical trial
A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 Days to Less Than 12 Weeks of Age With Autosomal Recessive Polycystic Kidney Disease (ARPKD)Status: Recruiting, Estimated PCD: 2027-10-11
Clinical trial
A Phase 3b, Two-part, Multicenter, One Year Randomized, Double-blind, Placebo-controlled Trial of the Safety, Pharmacokinetics, Tolerability, and Efficacy of Tolvaptan Followed by a Two Year Open-label Extension in Children and Adolescent Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)Status: Completed, Estimated PCD: 2021-11-17
Clinical trial
A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 Days to Less Than 18 Years of Age With Autosomal Recessive Polycystic Kidney Disease (ARPKD)Status: Recruiting, Estimated PCD: 2026-04-27
Clinical trial
Post-Marketing Surveillance(PMS) of Safety and Efficacy of Samsca® Tablets in Korean Patients With ADPKDStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) in JapanStatus: Recruiting, Estimated PCD: 2028-08-01
Clinical trial
Efficacy and Safety of Low-dose Tolvaptan in Treatment of Inpatient Hyponatraemia.Status: Recruiting, Estimated PCD: 2024-06-30